ECE2007 Poster Presentations (1) (659 abstracts)
A comparison of NCEP-ATP-III and IDF metabolic syndrome definitions with relation to metabolic syndrome associated sexual dysfunction
Giovanni Corona 1 , Edoardo Mannucci 2 , Luisa Petrone 1 , Francesco Lotti 1 , Alessandra D Fisher 1 , Giancarlo Balercia 3 , Valerio Chairini 4 , Gianni Forti 1 & Mario Maggi 1
1Andrology Unit, University of Florence, Florence, Italy; 2Geriatric Unit, Diabetes Section, University of Florence, Florence, Italy; 3Endocrinology Unit, Polytechnic University of Marche, Ancona, Italy; 4Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy.
Objectives: The aim of present study was to verify possible differences in the prevalence of vasculogenic ED and hypogonadism comparing two distinct new definitions of MetS, as National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and International diabetes Federation (IDF) in patients with sexual dysfunction.
Methods: Several hormonal, biochemical and instrumental (penile doppler ultrasound) parameters were studied. ANDROTEST Structured Interview was also applied. This a 12-item, recently validated, inventories, which assesses the degree of androgenization in male.
Results: We studied a consecutive series of 1086 patients. The prevalence of metabolic syndrome was 32.0% and 44.7% according to NCEP-ATPIII and IDF criteria, respectively. Patients with MetS according to both criteria reported lower PGE-1 stimulated penile flow (Vpmax). At multivariate analysis, only NCEP-ATPIII was significantly associated with Vpmax (B=−7.7±3.8; P<0.05). Patients with MetS defined according to both criteria reported lower total (13.6±6.0 vs. 17.4±7.2 and 14.7±7.4 vs. 18.2±6.0 nmol/l,) and free testosterone levels (34.8±14.0 vs. 40.8±13.7 and 36.2±14.1 vs. 42.5±13.5 pmol/l), higher prevalence of hypogonadism (34.3 vs. 11.9 and 25.3 vs. 8.7%), and higher ANDROTEST score (9.6±3.0 vs. 7.2±3.6 and 9.2±3.2 vs. 6.0±3.2) respectively for NCEP-ATPIII and IDF; all P<0.0001. However, when IDF, but not NCEP-ATPIII, criteria were fulfilled, the prevalence of hypogonadism was significantly lower than that observed in patients fulfilling both criteria (15.6 vs.34.8% respectively; P<0.0001). Conversely, those fulfilling NCEP-ATP-III, but not IDF, criteria did not show a significant different prevalence of hypogonadism than those positive for both sets of criteria (30.8 vs.34.8%; P=NS).
Conclusions: In patients with ED, NCEP-ATPII criteria seem to be a better predictor of hypogonadism and impaired penile blood flow than IDF.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more